Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | LYEL | Series AA Preferred Stock | Jun 16, 2021 | Common Stock | 30.3M | See footnote | F1, F2 |
Id | Content |
---|---|
F1 | The Series AA Preferred Stock is convertible into common stock on a 1-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election and automatically upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date. |
F2 | The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person"). |